CN Patent

CN116509868B — Vs6766联合bay293的应用及药物组合物

Assigned to West China Hospital of Sichuan University · Expires 2023-10-20 · 3y expired

What this patent protects

本发明提供了VS6766联合BAY293的应用及药物组合物，涉及生物医药技术领域。与RAF/MEK双靶点抑制剂VS6766单独使用或KRAS活性抑制剂BAY293单独使用相比，KRAS活性抑制剂BAY293联合RAF/MEK双靶点抑制剂VS6766的方案可有效抑制KRAS突变型肠癌细胞的增殖与存活，更有效地抑制KRAS下游MAPK通路与P13K通路的信号传导，二者具有协同抗肿瘤作用。二者可直接联合用药，也可制成组合制剂，用于治疗KRAS突变型肠癌，具有良好的临床转化前景。

USPTO Abstract

本发明提供了VS6766联合BAY293的应用及药物组合物，涉及生物医药技术领域。与RAF/MEK双靶点抑制剂VS6766单独使用或KRAS活性抑制剂BAY293单独使用相比，KRAS活性抑制剂BAY293联合RAF/MEK双靶点抑制剂VS6766的方案可有效抑制KRAS突变型肠癌细胞的增殖与存活，更有效地抑制KRAS下游MAPK通路与P13K通路的信号传导，二者具有协同抗肿瘤作用。二者可直接联合用药，也可制成组合制剂，用于治疗KRAS突变型肠癌，具有良好的临床转化前景。

Drugs covered by this patent

Patent Metadata

Patent number: CN116509868B
Jurisdiction: CN
Classification: —
Expires: 2023-10-20
Drug substance claim: No
Drug product claim: No
Assignee: West China Hospital of Sichuan University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.